LMS RESEARCH PROJECTS SUPPORTED BY THE NLMSF
“INVESTMENT” CONTRIBUTIONS IN ACTION:
McGill University, Montreal,
Development of the Multi-Omic Liquid Biopsy Assay
for the Pre-Operative Diagnosis of Uterine
Leiomyosarcoma and Benign Leiomyoma
German Cancer Research Center
NLMSF Grant for 2022-2023:
Matthew Hemming, M.D., Ph.D.
Dana Farber Cancer Institute/Harvard Medical School
“We are so grateful to the National Leiomyosarcoma Foundation for supporting out research! This support will allow us to develop and interrogate much needed laboratory models of leiomyosarcoma. For this first time, we will be using high-throughput drug screening approaches in patient samples and xenograft models to identify novel and targeted therapies, which we aim to translate into novel clinical trials and treatment options for patients. This urgently needed work wouldn’t be possible without the support form NLMSF!
NLMSF Grant for 2021-2022:
* Define the molecular mechanisms that regulate the accumulation and pathologic activation of TIM (Tumor-infiltrating myeloid cells) present in Human LMS.
to checkpoint blockage in a 3D human model of LMS.
ANNOUNCEMENT OF THE GRANT TO DR. LLOSA AT THE 2020 CTOS ANNUAL MEETINGBY THE NLMSF EXECUTIVE COMMITTEE MEMBER:
CANCER CELL LINE PROJECT / Dependency Map Project – BROAD INSTITUTE OF MIT/HARVARD
LMS. Evaluating patient response through a multidisciplinary approach to the evaluation of patient response to current treatment therapies continues to facilitate exploration of new/ more effective treatment options, and promotes the acceleration of treatment advancements for the full spectrum of the sarcoma population.
an analysis would enable clinicians to identify patients who could safely undergo laparoscopic procedures using power morcellators. A “liquid biopsy” test based on the analysis of tumor-associated genetic aberrations in circulating tumor DNA (ctDNA) in plasma maybe of great use such situations.
Maximizing Therapeutic Response in Leiomyosarcoma:
Gonzalo Lopez, Ph.D. of the Solove Cancer Institute, James Cancer Center, Ohio State University. Dr. Lopez’s study is summarized as follows:
- Robert Dauchy studies Planetary Geology, Human Factors in Aviation, and Aviation History (Transport History). … experimental cancers in vivo is inhibited by either physiological or pharmacological levels of the pineal gland hormone melatonin, although the. … Robert T. Dauchy, Eugene W. Holowachuk. and Mary S. Ruhoff Bassett Research …
- Antineoplastic effects of melatonin on a rare malignancy of mesenchymal origin: melatonin receptor-
mediated inhibition of signal transduction, linoleic acid metabolism and growth in tissue-isolated human leiomyosarcoma xenografts. … Address reprint requests to Robert T. Dauchy, Laboratory of Chrono-Neuroendocrine Oncology, Department of …
THE NLMSF SUMMARY OF RESEARCH FUNDING SUPPORT SINCE THE BEGINNING . . . . .
Stanford University – Matt van de Rijn, M.D., Ph.D.
DONATIONS ARE MAKING!